Provided are powder blend formulations or oral solutions comprising N-{ 3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl} acetamide dimethyl sulfoxide solvate (trametinib dimethyl sulfoxide, GSK1120212B). The formulations or solutions may comprise hydroxypropyl B-cyclodextrin sulfobutylether B-cyclodextrin a combination of hydroxypropyl B-cyclodextrin and sulfobutylether B-cyclodextrin a combination of hydroxypropyl B-cyclodextrin and hypromellose a combination of sulfobutylether B-cyclodextrin and hypromellose or hypromellose as a solubilizer. The compound is an anti-cancer agent.
